Hope for resistant hypertension through BrigHTN and PRECISION

Nature Reviews Nephrology, Published online: 19 January 2023; doi:10.1038/s41581-023-00676-2An estimated 10–15% of individuals with hypertension are resistant to available antihypertensive therapies. Findings from two new clinical trials — BrigHTN and PRECISION — that assessed the blood pressure-lowering effects of the aldosterone synthase inhibitor baxdrostat and the dual endothelin receptor antagonist aprocitentan, respectively, suggest these approaches hold promise for patients with treatment-resistant hypertension.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research